Pharming Group (NASDAQ:PHAR) Stock Price Down 4.6% - What's Next?

Key Points

• Pharming Group's stock price has decreased by 4.6%, trading at $15.39 with reduced trading volume of 3,462 shares, down 53% from its average.
• Analysts recently downgraded Pharming Group from a "strong-buy" to a "hold" rating, while the consensus target price remains at $30.00.
• The company reported $93.20 million in revenue for the quarter, significantly exceeding the expected $70.36 million, and has set FY 2025 EPS guidance at -0.2.

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report) dropped 4.6% during mid-day trading on Monday . The company traded as low as $15.46 and last traded at $15.39. Approximately 3,462 shares changed hands during trading, a decline of 53% from the average daily volume of 7,386 shares. The stock had previously closed at $16.14.

Analyst Upgrades and Downgrades

PHAR has been the subject of a number of recent research reports. Zacks Research lowered Pharming Group from a "strong-buy" rating to a "hold" rating in a report on Tuesday, September 30th. Weiss Ratings reaffirmed a "sell (d+)" rating on shares of Pharming Group in a report on Saturday, September 27th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $30.00.

Pharming Group Stock Down 4.7%

The company has a 50 day moving average price of $13.43 and a two-hundred day moving average price of $11.02. The company has a debt-to-equity ratio of 0.38, a current ratio of 2.79 and a quick ratio of 2.07. The stock has a market cap of $1.05 billion, a PE ratio of -118.31 and a beta of 0.04.

Pharming Group (NASDAQ:PHAR - Get Free Report) last announced its earnings results on Thursday, July 31st. The company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.16. The business had revenue of $93.20 million for the quarter, compared to analysts' expectations of $70.36 million. Pharming Group had a negative return on equity of 3.31% and a negative net margin of 2.19%. Pharming Group has set its FY 2025 guidance at EPS. Analysts expect that Pharming Group N.V. Sponsored ADR will post -0.2 EPS for the current year.

Hedge Funds Weigh In On Pharming Group

A hedge fund recently bought a new stake in Pharming Group stock. EverSource Wealth Advisors LLC purchased a new stake in shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 2,979 shares of the company's stock, valued at approximately $32,000. 0.03% of the stock is owned by institutional investors and hedge funds.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.